// App-Quantinova.ai

5183 : Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model

Researchers

Presenter

  • Kyle C. McElyea

Principal Investigators

  • Max H. Jacobsen

  • Max Schmidt

  • Huiwen Cheng

  • Mark R. Kelley

  • George E. Sandusky

  • Melissa L. Fishel

Medical Centers

  • Indiana University School of Medicine, Indianapolis, IN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

  • Pancreatic and cerebellar agenesis

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • Nuclear factor kappa-light-chain-enhancer of activated B cells

  • JunB proto-oncogene, AP-1 transcription factor subunit

  • Signal transducer and activator of transcription 3

Drug/Treatment

  • Gemcitabine

  • E-3330

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved